OCGN

Ocugen Inc. (OCGN) | Rumor.io

Ocugen

OCGN

Attention (50-day avg)0.03%

Attention rank (50-day avg)#214

Bullish sentiment (50-day avg)76%

Price to earnings ratio-4.48

Market capitalization349.3M

Earnings per share-0.26

Dividend yield (TTM)—

Revenue (annual)4.4M

Net income (annual)-67.8M

Social

What share of all stock conversation is about OCGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% -0.01	0.02% -0.04	0.04% +0.02	0.04% -0.01

Sep 29

OCU400, a treatment for retinitis pigmentosa, may have a private pay market of 1,500 potential patients, generating $3 billion in treatment sales at $2 million per treatment.
The company Ocugen, Inc. has a strong potential in the biotechnology and gene therapy landscape, with its chairman, CEO, and Co-Founder, Shankar Musunuri, participating in industry conferences to share perspectives on the evolving landscape.
The retinitis pigmentosa market is expected to grow with a focus on disease-modifying therapies, as stated in a DelveInsight report, with the market outlook strengthening during the forecast period (2026-2036).

Generated by AI

Sentiment

Of the messages about OCGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	83.82% +16.34	65.84% +1.93	70.05% -18.71	91.72% +1.59
Bearish	16.18% -16.34	34.16% -1.93	29.95% +18.71	8.28% -1.59

Bullish· Sep 29

The company's OCU400 treatment has a solid approval process, and the private pay market for this treatment could be substantial, potentially generating $3 billion in sales.
The treatment's potential patient pool is estimated to be around 1,500 individuals, which could lead to significant revenue growth, even considering a conservative 10% market capture.
The company's revenue has shown significant increases, with a 684% increase in Q1 2027 compared to Q1 2026, and the author believes that the news will come over the next two years, leading to a significant increase in the stock price.

Bearish· Sep 29

The CEO of Ocugen, Inc. (OCGN) sold over 520k shares in September, despite promising potential approvals and a massive stock rally, and is now asking for 250M new shares to fund his salary.
The company has not brought a single product to market in over 13 years, with the CEO still collecting his paycheck and begging for more shares, earning the label "Dilution as a Business Model".
The stock has dropped significantly, and the CEO's actions, including selling shares and asking for more, have led to a loss of trust among investors, with some predicting the company will file for a BLA (Biologics License Application) and others calling it a "SCAM".

Generated by AI

Topics

Of the messages about OCGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	90.82%	3.5%	7.88%
Technical Analysis	0%	7.65%	32.69%	39.51%
Analysts	0%	1.53%	31.99%	26.35%
Earnings	0%	0%	0%	0.14%
Macro	0%	0%	31.79%	26.06%
Controversies	0%	0%	0.04%	0.06%

Earnings· Feb 25

OCGN reported Q4 earnings with a loss of $0.07, in line with expectations.
The company will issue a pre-market earnings announcement on the same day as the call, with details available on the Ocugen website.
Investors are invited to participate on the call, which will provide further information on the company's business update and potential catalysts for growth.

Analysts· Mar 1

Chardan Capital upgraded Ocugen to Buy, citing an attractive entry point ahead of catalysts, and set a price target of $3.50.
Analysts at Chardan, Mizuho, and HC Wainwright have all issued Buy ratings for Ocugen, with price targets ranging from $3 to $5.
The buy consensus among 12 analysts is 80%, indicating mild confidence in Ocugen, with analysts citing the company's ophthalmic gene therapy programs and upcoming catalysts as key drivers.

Announcements· Jul 13

Ocugen signs a binding term sheet to license OCU400, a modifier gene therapy for retinitis pigmentosa, in the Middle East and North Africa (MENA) region, with Roots Pharmaceutical and Al-Dhow International Holding, for up to $4M in upfront and near-term development milestones, and up to $255M in sales milestones, plus a 22% royalty on net sales.
The deal allows Ocugen to manufacture and supply OCU400, with the partner responsible for commercialization in the MENA region, providing a long-term revenue stream beyond royalties.
This is the second regional licensing transaction for OCU400, following the Korean deal announced in 2025, and provides third-party validation of the commercial value of OCU400 in the region.

Controversies· Mar 4

The FDA declined to issue an Emergency Use Authorization (EUA) for Ocugen's (OCGN) COVID-19 vaccine, COVAXIN, for individuals 2 to 18 years of age.
The rejection of the EUA has led to speculation about potential favoritism towards mRNA vaccines, with some calling for a senate investigation and the revocation of immunity for these vaccines.
The decision has also raised questions about the influence of former Pfizer employee, Peter Marks, who is now in charge of FDA drug approvals, and the potential role of Dr. Anthony Fauci in the approval process.

Macro· May 13

*The World Health Organization has cited studies suggesting that Covaxin, an Indian-developed vaccine, is effective against the double mutant strain of the coronavirus, while Pfizer and Moderna vaccines may not be as effective.*
*The US government may commit to purchasing Covaxin doses and using the Defense Production Act to manufacture the vaccine in the US, making the country a "medicine cabinet for the world."*
*Covaxin's effectiveness against the Indian variant and its ability to be administered to children as young as 2 years old make it a promising vaccine option, potentially replacing synthetic vaccines that require booster shots.*

Technical Analysis· Mar 17

$OCGN has held above all daily moving averages, showing real demand from buyers.
The stock has shown above-average constant volume over the past couple of days, indicating potential price movement.
A doji candle was seen today, which could be a precursor to a price increase, potentially reaching the $5s if it breaks above $2.69.

Generated by AI

Community

Of the messages about OCGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	97.11%	92.75%	97.56%	80.74%
Newcomers	2.89%	7.25%	2.44%	19.26%

Regulars· Sep 29

The potential private pay market for OCU400 in the Bahamas could be significant, with a possible 1,500 patients at $2M per treatment, and a potential $3 billion in treatment sales, capturing just 10% of the market.
The regulars are focused on the potential number of people willing to travel to the Bahamas for OCU400, and the rough estimate of 0.095% of the world's population with $5M+ in investable assets, which could lead to 1,500 potential private pay patients.
The focus on the potential treatment sales and market size is emphasized, with the regulars noting that it doesn't take many patients to become very meaningful, and ignoring factors such as financing, insurance, government funding, and charities.

Newcomers· Sep 18

Newcomers are discussing the potential for a short squeeze in OCGN, with some asking when it will happen.
The newcomers are focused on the recent bullish momentum in OCGN, with many loading up on the stock and expecting a further run.
There is also discussion about the potential for dilution in OCGN, with some users questioning when analysts' target prices will be lowered.

Generated by AI

News

Ocugen Inc. stock rises Tuesday, outperforms market

14h agomarketwatch.com

Analysts Conflicted on These Healthcare Names: Ocugen (OCGN), Aveanna Healthcare Holdings (AVAH) and Universal Health (UHS)

Detailed price information for Universal Health Services (UHS-N) from The Globe and Mail including charting and trades.

22h agoThe Globe and Mail

H.C. Wainwright raises Ocugen stock price target on Bahamas approval

1d agoInvesting.com

Ocugen Inc. stock rises Friday, outperforms market

4d agoMarketWatch

Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days

Ocugen is building an international pathway for OCU400 ahead of key Phase 3 data and a planned U.S. regulatory filing next year.

4d agofinance.yahoo.com

Ocugen receives provisional approval for gene therapy in Bahamas

5d agoInvesting.com

Also Discussed

Investors talking about OCGN also mention

#	Name	Attention
1	Bionano Genomics Inc.BNGO	0%0
2	Castor Maritime Inc.CTRM	0%0
3	VXRT - Vaxart, Inc.	——
4	Jaguar Health, Inc.JAGX	0.02%-0.02
5	Oragenics Inc.OGEN	0%0
6	METX - Meten Holding Group Ltd.	——
7	Phunware, Inc.PHUN	0%0
8	GHSI - Guardion Health Sciences, Inc.	——
9	SOS LimitedSOS	0%0
10	OBLN - Obalon Therapeutics, Inc.	——

Ocugen Inc.

Healthcare
Biotechnology

Ocugen Inc. is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for blindness diseases and other serious ocular conditions. Its current programs center on a modifier gene therapy platform designed to address inherited retinal diseases and multifactorial eye disorders, including retinitis pigmentosa, Stargardt disease, and geographic atrophy. The company also works on cell therapy and vaccine-related research through selective programs and collaborations, reflecting a broader focus on unmet medical needs in ophthalmology and infectious disease. Ocugen’s pipeline includes product candidates under clinical development rather than marketed therapies, so its role in the market is primarily tied to research, development, and partnership-driven innovation. Headquartered in Malvern, Pennsylvania, Ocugen Inc. operates as a biotechnology company concentrated on advancing treatments for patients with limited current options.

Website

Location

11 Great Valley Parkway

Malvern, PA, 19355

United States

Social

What share of all stock conversation is about OCGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% -0.01	0.02% -0.04	0.04% +0.02	0.04% -0.01

Sep 29

OCU400, a treatment for retinitis pigmentosa, may have a private pay market of 1,500 potential patients, generating $3 billion in treatment sales at $2 million per treatment.
The company Ocugen, Inc. has a strong potential in the biotechnology and gene therapy landscape, with its chairman, CEO, and Co-Founder, Shankar Musunuri, participating in industry conferences to share perspectives on the evolving landscape.
The retinitis pigmentosa market is expected to grow with a focus on disease-modifying therapies, as stated in a DelveInsight report, with the market outlook strengthening during the forecast period (2026-2036).

Generated by AI

Sentiment

Of the messages about OCGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	83.82% +16.34	65.84% +1.93	70.05% -18.71	91.72% +1.59
Bearish	16.18% -16.34	34.16% -1.93	29.95% +18.71	8.28% -1.59

Bullish· Sep 29

The company's OCU400 treatment has a solid approval process, and the private pay market for this treatment could be substantial, potentially generating $3 billion in sales.
The treatment's potential patient pool is estimated to be around 1,500 individuals, which could lead to significant revenue growth, even considering a conservative 10% market capture.
The company's revenue has shown significant increases, with a 684% increase in Q1 2027 compared to Q1 2026, and the author believes that the news will come over the next two years, leading to a significant increase in the stock price.

Bearish· Sep 29

The CEO of Ocugen, Inc. (OCGN) sold over 520k shares in September, despite promising potential approvals and a massive stock rally, and is now asking for 250M new shares to fund his salary.
The company has not brought a single product to market in over 13 years, with the CEO still collecting his paycheck and begging for more shares, earning the label "Dilution as a Business Model".
The stock has dropped significantly, and the CEO's actions, including selling shares and asking for more, have led to a loss of trust among investors, with some predicting the company will file for a BLA (Biologics License Application) and others calling it a "SCAM".

Generated by AI

Topics

Of the messages about OCGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	90.82%	3.5%	7.88%
Technical Analysis	0%	7.65%	32.69%	39.51%
Analysts	0%	1.53%	31.99%	26.35%
Earnings	0%	0%	0%	0.14%
Macro	0%	0%	31.79%	26.06%
Controversies	0%	0%	0.04%	0.06%

Earnings· Feb 25

OCGN reported Q4 earnings with a loss of $0.07, in line with expectations.
The company will issue a pre-market earnings announcement on the same day as the call, with details available on the Ocugen website.
Investors are invited to participate on the call, which will provide further information on the company's business update and potential catalysts for growth.

Analysts· Mar 1

Chardan Capital upgraded Ocugen to Buy, citing an attractive entry point ahead of catalysts, and set a price target of $3.50.
Analysts at Chardan, Mizuho, and HC Wainwright have all issued Buy ratings for Ocugen, with price targets ranging from $3 to $5.
The buy consensus among 12 analysts is 80%, indicating mild confidence in Ocugen, with analysts citing the company's ophthalmic gene therapy programs and upcoming catalysts as key drivers.

Announcements· Jul 13

Ocugen signs a binding term sheet to license OCU400, a modifier gene therapy for retinitis pigmentosa, in the Middle East and North Africa (MENA) region, with Roots Pharmaceutical and Al-Dhow International Holding, for up to $4M in upfront and near-term development milestones, and up to $255M in sales milestones, plus a 22% royalty on net sales.
The deal allows Ocugen to manufacture and supply OCU400, with the partner responsible for commercialization in the MENA region, providing a long-term revenue stream beyond royalties.
This is the second regional licensing transaction for OCU400, following the Korean deal announced in 2025, and provides third-party validation of the commercial value of OCU400 in the region.

Controversies· Mar 4

The FDA declined to issue an Emergency Use Authorization (EUA) for Ocugen's (OCGN) COVID-19 vaccine, COVAXIN, for individuals 2 to 18 years of age.
The rejection of the EUA has led to speculation about potential favoritism towards mRNA vaccines, with some calling for a senate investigation and the revocation of immunity for these vaccines.
The decision has also raised questions about the influence of former Pfizer employee, Peter Marks, who is now in charge of FDA drug approvals, and the potential role of Dr. Anthony Fauci in the approval process.

Macro· May 13

*The World Health Organization has cited studies suggesting that Covaxin, an Indian-developed vaccine, is effective against the double mutant strain of the coronavirus, while Pfizer and Moderna vaccines may not be as effective.*
*The US government may commit to purchasing Covaxin doses and using the Defense Production Act to manufacture the vaccine in the US, making the country a "medicine cabinet for the world."*
*Covaxin's effectiveness against the Indian variant and its ability to be administered to children as young as 2 years old make it a promising vaccine option, potentially replacing synthetic vaccines that require booster shots.*

Technical Analysis· Mar 17

$OCGN has held above all daily moving averages, showing real demand from buyers.
The stock has shown above-average constant volume over the past couple of days, indicating potential price movement.
A doji candle was seen today, which could be a precursor to a price increase, potentially reaching the $5s if it breaks above $2.69.

Generated by AI

Community

Of the messages about OCGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	97.11%	92.75%	97.56%	80.74%
Newcomers	2.89%	7.25%	2.44%	19.26%

Regulars· Sep 29

The potential private pay market for OCU400 in the Bahamas could be significant, with a possible 1,500 patients at $2M per treatment, and a potential $3 billion in treatment sales, capturing just 10% of the market.
The regulars are focused on the potential number of people willing to travel to the Bahamas for OCU400, and the rough estimate of 0.095% of the world's population with $5M+ in investable assets, which could lead to 1,500 potential private pay patients.
The focus on the potential treatment sales and market size is emphasized, with the regulars noting that it doesn't take many patients to become very meaningful, and ignoring factors such as financing, insurance, government funding, and charities.

Newcomers· Sep 18

Newcomers are discussing the potential for a short squeeze in OCGN, with some asking when it will happen.
The newcomers are focused on the recent bullish momentum in OCGN, with many loading up on the stock and expecting a further run.
There is also discussion about the potential for dilution in OCGN, with some users questioning when analysts' target prices will be lowered.

Generated by AI

Ocugen

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 29

Earnings· Feb 25

Analysts· Mar 1

Announcements· Jul 13

Controversies· Mar 4

Macro· May 13

Technical Analysis· Mar 17

Regulars· Sep 29

Newcomers· Sep 18

Ocugen Inc. stock rises Tuesday, outperforms market

Analysts Conflicted on These Healthcare Names: Ocugen (OCGN), Aveanna Healthcare Holdings (AVAH) and Universal Health (UHS)

H.C. Wainwright raises Ocugen stock price target on Bahamas approval

Ocugen Inc. stock rises Friday, outperforms market

Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days

Ocugen receives provisional approval for gene therapy in Bahamas

Also Discussed

Ocugen Inc.

Company Information

Location

Ocugen Inc. stock rises Tuesday, outperforms market

Analysts Conflicted on These Healthcare Names: Ocugen (OCGN), Aveanna Healthcare Holdings (AVAH) and Universal Health (UHS)

H.C. Wainwright raises Ocugen stock price target on Bahamas approval

Ocugen Inc. stock rises Friday, outperforms market

Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days

Ocugen receives provisional approval for gene therapy in Bahamas

Also Discussed

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 29

Earnings· Feb 25

Analysts· Mar 1

Announcements· Jul 13

Controversies· Mar 4

Macro· May 13

Technical Analysis· Mar 17

Regulars· Sep 29

Newcomers· Sep 18